EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB

Seong Hee Kang, Hyung Joon Yim iD, Seul Ki Han, Sun Young Yim, Tae Hyung Kim, Young-Sun Lee iD, Seung Kak Shin iD, Young Kul Jung, Moon Young Kim iD, Ji Hoon Kim, Yeon Seok Seo iD, Oh Sang Kwon und 2 weitere

Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1583-1589

DOI: 10.1111/jgh.70326 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 08.03.2026. Verfasst von Seong Hee Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Tenofovir, Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea University Ansan Hospital Grant, National Research Foundation of Korea (NRF) grant funded by the Korean government, Korea University Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are guideline‐endorsed first‐line options for antiviral‐naive chronic hepatitis B (CHB). We compared their associations with hepatocellular carcinoma (HCC) occurrence.

Methods

We assembled a multicenter cohort of 1364 treatment‐naive CHB patients initiating either TAF ( n = 322) or TDF ( n = 1042) between 2012 and 2019. Confounding was addressed using 1:2 propensity score (PS) matching and inverse probability of treatment weighting (IPTW).

Results

The PS‐matched analytic set comprised 966 patients (TAF 322; TDF 644). Over 60 months, nine HCC events occurred (two TAF and seven TDF events). Crude incidence rates were 0.17 and 0.27 per 100 person‐years for TAF and TDF, respectively. Five‐year cumulative risks were 0.6% (TAF) versus 1.0% (TDF). In multivariable models, TAF remained protective (adjusted hazard ratio [aHR]: 0.29, 95% confidence interval [CI]: 0.13–0.66; p < 0.01). Findings were directionally consistent across subgroups, with the strongest associations observed among patients without diabetes, those who were hepatitis B e antigen–positive, and those with baseline HBV DNA in the 5–8 log10 IU/mL range. In IPTW analyses, TAF was likewise associated with lower HCC risk (aHR: 0.31, 95% CI: 0.14–0.68; p < 0.01).

Conclusions

Compared with TDF, TAF use was associated with an approximately 71% reduction in HCC hazard. Larger cohorts with longer follow‐up are warranted to corroborate these observations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirCarcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicAdenineAntiviral AgentsHumansAlanineFemaleMaleMiddle AgedAdultRiskIncidenceCohort Studies

Stichwörter der Autor:innen

chronic hepatitis Bhepatocellular carcinomatenofovir alafenamidetenofovir disoproxil fumarate

Substanzen

Tenofovirtenofovir alafenamideAlanineAdenineAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
  • Department of Internal Medicine, Gachon University College of Medicine, Incheon, Republic of Korea.

ORCID-Profile: Hyung Joon Yim, Young-Sun Lee, Seung Kak Shin, Moon Young Kim, Yeon Seok Seo

Förderung

  • Korea University Ansan Hospital Grant
  • National Research Foundation of Korea (NRF) grant funded by the Korean government
  • Korea University Research Grant
  • Basic Science Research Program through the National Research Foundation of Korea
  • Medical Research Center Program
  • Ministry of Science, ICT, and Future Planning
  • The Korean Association for the Study of the Liver
  • The Korean Liver Foundation

Zitieren

APA

Kang, S. H., Yim, H. J., Han, S. K., Yim, S. Y., Kim, T. H., Lee, Y. S., Shin, S. K., Jung, Y. K., Kim, M. Y., Kim, J. H., Seo, Y. S., Kwon, O. S., Yeon, J. E., & Baik, S. K. (2026). Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. Journal of Gastroenterology and Hepatology, 41(5), 1583-1589. https://doi.org/10.1111/jgh.70326

Vancouver

Kang SH, Yim HJ, Han SK, Yim SY, Kim TH, Lee YS, et al. Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. Journal of Gastroenterology and Hepatology. 2026;41(5):1583-1589. doi:10.1111/jgh.70326

BibTeX
@article{Kang2026,
  author = {Kang, Seong Hee and Yim, Hyung Joon and Han, Seul Ki and Yim, Sun Young and Kim, Tae Hyung and Lee, Young-Sun and Shin, Seung Kak and Jung, Young Kul and Kim, Moon Young and Kim, Ji Hoon and Seo, Yeon Seok and Kwon, Oh Sang and Yeon, Jong Eun and Baik, Soon Koo},
  title = {Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  volume = {41},
  number = {5},
  pages = {1583--1589},
  doi = {10.1111/jgh.70326}
}
Kostenlos starten →